HC Wainwright reaffirmed their buy rating on shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) in a research note released on Wednesday morning. They currently have a $10.00 price objective on the stock.
Other equities analysts also recently issued research reports about the company. Canaccord Genuity set a $10.00 target price on Aurinia Pharmaceuticals and gave the company a buy rating in a report on Friday, August 5th. Leerink Swann reiterated an outperform rating and issued a $7.00 target price on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 6th. Finally, FBR & Co reiterated an outperform rating and issued a $9.00 target price on shares of Aurinia Pharmaceuticals in a report on Monday, August 15th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $7.75.
Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at 4.70 on Wednesday. The company has a 50 day moving average of $2.45 and a 200-day moving average of $2.78. The company’s market cap is $165.84 million. Aurinia Pharmaceuticals has a 52 week low of $1.42 and a 52 week high of $5.69.
A hedge fund recently raised its stake in Aurinia Pharmaceuticals stock. Lombard Odier Asset Management USA Corp boosted its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) by 2.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 102,294 shares of the company’s stock after buying an additional 2,813 shares during the period. Lombard Odier Asset Management USA Corp owned approximately 0.29% of Aurinia Pharmaceuticals worth $283,000 at the end of the most recent reporting period. 20.04% of the stock is owned by institutional investors and hedge funds.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.